Market Closed -
Hong Kong S.E.
04:09:00 2024-05-03 am EDT
|
5-day change
|
1st Jan Change
|
0.025
HKD
|
0.00%
|
|
+8.70%
|
-26.47%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
1,837
|
801.7
|
1,039
|
690.8
|
393.3
|
352.9
|
Enterprise Value (EV)
1 |
1,262
|
399.3
|
741.8
|
518.6
|
166.3
|
211.4
|
P/E ratio
|
365
x
|
-36.7
x
|
-2.93
x
|
-17.3
x
|
167
x
|
-2.86
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.1
x
|
3.31
x
|
4.13
x
|
3.76
x
|
1.88
x
|
1.84
x
|
EV / Revenue
|
5.57
x
|
1.65
x
|
2.95
x
|
2.82
x
|
0.79
x
|
1.1
x
|
EV / EBITDA
|
-954
x
|
-16.1
x
|
-32
x
|
-17.7
x
|
-2.74
x
|
-4.22
x
|
EV / FCF
|
496
x
|
-14.7
x
|
-48.1
x
|
-12.9
x
|
-2.32
x
|
-28.3
x
|
FCF Yield
|
0.2%
|
-6.81%
|
-2.08%
|
-7.77%
|
-43%
|
-3.54%
|
Price to Book
|
1.76
x
|
0.8
x
|
1.62
x
|
1.09
x
|
0.6
x
|
0.73
x
|
Nbr of stocks (in thousands)
|
5,101,609
|
5,042,139
|
5,042,139
|
5,042,139
|
5,042,139
|
5,042,139
|
Reference price
2 |
0.3600
|
0.1590
|
0.2060
|
0.1370
|
0.0780
|
0.0700
|
Announcement Date
|
4/16/18
|
4/16/19
|
4/29/20
|
4/30/21
|
4/29/22
|
4/28/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
226.7
|
241.9
|
251.6
|
183.8
|
209.6
|
191.5
|
EBITDA
1 |
-1.323
|
-24.85
|
-23.17
|
-29.3
|
-60.68
|
-50.07
|
EBIT
1 |
-5.802
|
-32.64
|
-35.08
|
-42.21
|
-77.93
|
-72.24
|
Operating Margin
|
-2.56%
|
-13.49%
|
-13.94%
|
-22.96%
|
-37.17%
|
-37.72%
|
Earnings before Tax (EBT)
1 |
13.6
|
-19.26
|
-362.7
|
-41.47
|
11.2
|
-171
|
Net income
1 |
3.911
|
-22.04
|
-354.7
|
-39.69
|
2.359
|
-123.3
|
Net margin
|
1.73%
|
-9.11%
|
-140.96%
|
-21.59%
|
1.13%
|
-64.4%
|
EPS
2 |
0.000985
|
-0.004335
|
-0.0703
|
-0.007899
|
0.000467
|
-0.0245
|
Free Cash Flow
1 |
2.545
|
-27.18
|
-15.42
|
-40.28
|
-71.58
|
-7.476
|
FCF margin
|
1.12%
|
-11.23%
|
-6.13%
|
-21.92%
|
-34.14%
|
-3.9%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
65.07%
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/16/18
|
4/16/19
|
4/29/20
|
4/30/21
|
4/29/22
|
4/28/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
575
|
402
|
297
|
172
|
227
|
142
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
2.54
|
-27.2
|
-15.4
|
-40.3
|
-71.6
|
-7.48
|
ROE (net income / shareholders' equity)
|
0.72%
|
-2.15%
|
-43.1%
|
-6.31%
|
-1.85%
|
-29.8%
|
ROA (Net income/ Total Assets)
|
-0.43%
|
-1.87%
|
-2.45%
|
-3.58%
|
-5.63%
|
-5.19%
|
Assets
1 |
-913.1
|
1,178
|
14,472
|
1,108
|
-41.87
|
2,375
|
Book Value Per Share
2 |
0.2000
|
0.2000
|
0.1300
|
0.1300
|
0.1300
|
0.1000
|
Cash Flow per Share
2 |
0.1100
|
0.0400
|
0.0500
|
0.0400
|
0.0500
|
0.0300
|
Capex
1 |
11.3
|
27.2
|
15
|
7.65
|
13.8
|
13.4
|
Capex / Sales
|
4.97%
|
11.24%
|
5.95%
|
4.16%
|
6.58%
|
6.99%
|
Announcement Date
|
4/16/18
|
4/16/19
|
4/29/20
|
4/30/21
|
4/29/22
|
4/28/23
|
|
1st Jan change
|
Capi.
|
---|
| -26.47% | 16.14M | | -13.79% | 20.6B | | -4.15% | 17.33B | | +7.42% | 13.89B | | +9.73% | 10.21B | | +7.47% | 1.82B | | +37.40% | 1.68B | | +18.37% | 617M | | 0.00% | 434M | | +33.65% | 154M |
Medical Prosthetics
|